AspenBio Pharma, Inc. Engages Comprehensive Investor Relations Firm

CASTLE ROCK, Colo., Dec. 14 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. today announced that it has retained financial PR firm Liolios Group, Inc., of Newport Beach, CA, to provide comprehensive shareholder and investor relations services. As the Company’s strategic shareholder communications partner, Liolios Group’s team of professionals will work closely with AspenBio Pharma management to develop a detailed and comprehensive investor relations program encompassing financial news, quarterly conference calls, research procurement, and proactive outreach to increase awareness of the Company.

“Liolios Group brings to us over 10 years of industry experience and expertise in helping small and micro-cap companies build quality, long-term relationships with leading analysts, money managers, and institutions to enhance our efforts to communicate with our current shareholders and broaden our investor audience,” stated Richard Donnelly, Chief Executive Officer and President of AspenBio Pharma. “We chose Liolios Group because of its proven track record of successfully working with companies to increase awareness throughout the investment community, the financial media, and our target markets.”

About AspenBio Pharma, Inc.

AspenBio Pharma, Inc., is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture and marketing of novel patented products that both enhance the reproductive efficiency of animals and have large worldwide market potential. The company was founded to produce purified proteins for diagnostic applications and is now a leading supplier of human hormones to many of the nation’s largest medical diagnostic companies and research institutions. The company has successfully leveraged this science and technology expertise in reproduction hormones to rapidly develop an enviable late-stage pipeline of 4 novel reproduction analogs for wide-ranging therapeutic use in bovine and equine species. The company has also created an early pregnancy status diagnostic for dairy cows which is currently in late-stage development (www.aspenbioinc.com).

ABOUT LIOLIOS GROUP, INC.

Liolios Group, Inc., is a highly selective investor relations firm specializing in small and micro-cap companies. Liolios Group systematically works with a select number of clients allowing an increased focus and significant company exposure. This selectivity and unique approach is unparalleled, and allows Liolios Group to deliver superior performance in corporate positioning, investor awareness, and capital formation. For more information visit www.liolios.com

This news release includes “forward looking statements” of AspenBio Pharma, Inc. (“APNB”) as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APNB believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APNB believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APNB. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including development of new products, obtaining additional funding, adverse changes in market conditions, fluctuations in sales volumes, and problems in collecting receivables. Furthermore, APNB does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APNB’s recent filings with the SEC.

Contacts: For more information contact: AspenBio Pharma, Inc. Richard Donnelly, CEO 303/794-2000 Investor Relations Liolios Group, Inc. Scott Liolios or Ron Both 949-574-3860

AspenBio Pharma, Inc.

CONTACT: Richard Donnelly, CEO of AspenBio Pharma, Inc., +1-303-794-2000;or investors, Scott Liolios or Ron Both, both of Liolios Group, Inc.,+1-949-574-386, for AspenBio Pharma, Inc.

MORE ON THIS TOPIC